Eli Lilly and Company $LLY Stock Position Lowered by Financial Life Planners

Financial Life Planners trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 18.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,202 shares of the company’s stock after selling 281 shares during the period. Eli Lilly and Company accounts for 0.8% of Financial Life Planners’ investment portfolio, making the stock its 20th biggest holding. Financial Life Planners’ holdings in Eli Lilly and Company were worth $937,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Lazard Freres Gestion S.A.S. boosted its position in shares of Eli Lilly and Company by 114.3% in the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after acquiring an additional 41,222 shares during the period. Precedent Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the period. Capital Advisors Inc. OK grew its position in shares of Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after purchasing an additional 429 shares in the last quarter. Family CFO Inc bought a new position in shares of Eli Lilly and Company during the second quarter worth approximately $54,000. Finally, Duquesne Family Office LLC raised its position in shares of Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several analyst reports. Scotiabank started coverage on Eli Lilly and Company in a report on Thursday. They issued a “sector outperform” rating and a $1,165.00 price objective for the company. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, November 3rd. BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. HSBC raised their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Finally, Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $886.00 to $1,104.00 in a report on Monday, November 10th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $999.28.

Eli Lilly and Company Trading Up 0.2%

LLY opened at $1,024.67 on Friday. The company has a market cap of $968.70 billion, a P/E ratio of 66.97, a PEG ratio of 1.21 and a beta of 0.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company’s 50 day moving average is $826.89 and its 200-day moving average is $780.87. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,033.62.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s revenue was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.